Biogen traded at $219.64 this Tuesday August 16th, decreasing $2.74 or 1.23 percent since the previous trading session. Looking back, over the last four weeks, Biogen lost 2.47 percent. Over the last 12 months, its price fell by 37.21 percent. Looking ahead, we forecast Biogen to be priced at 214.80 by the end of this quarter and at 197.26 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
219.64
Daily Change
-1.23%
Yearly
-37.21%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 142.55 0.26 0.18% 19.13%
Acadia Pharmaceuticals 16.96 0.36 2.17% -1.62%
Acorda Therapeutics 0.47 0.004 0.75% -86.86%
ALKERMES 26.45 -0.15 -0.56% -9.08%
Amgen 253.15 2.07 0.82% 9.49%
Bayer 53.91 -0.39 -0.72% 12.51%
Biogen 219.64 -2.74 -1.23% -37.21%
Bluebird Bio 6.58 -0.25 -3.66% -64.85%
BioMarin Pharmaceutical 95.03 -1.91 -1.97% 24.45%
Bristol-Myers Squibb 74.13 -0.40 -0.54% 7.50%
Esperion Therapeutics 6.85 0.18 2.70% -51.96%
Gilead Sciences 66.33 0.12 0.18% -9.17%
Intercept Pharmaceuticals 18.07 -0.12 -0.66% 31.71%
Incyte Corp 74.96 -0.32 -0.43% -0.93%
Intra Cellular Therapies 53.81 1.28 2.44% 77.18%
Eli Lilly 310.31 -3.63 -1.16% 13.79%
Merck & Co 90.59 -0.01 -0.01% 16.45%
Moderna Inc 167.96 -8.82 -4.99% -58.20%
Marinus Pharmaceuticals 6.03 0.35 6.16% -49.92%
Neurocrine Biosciences 106.11 -1.28 -1.19% 15.58%
Novartis 81.21 0.23 0.28% -6.38%
Puma Biotechnology 3.27 -0.18 -5.22% -54.71%
Pfizer 49.86 0.11 0.22% -1.11%
PTC Therapeutics 51.86 -1.06 -2.00% 32.19%
Ultragenyx Pharmaceutical 49.31 -1.89 -3.69% -44.41%
Regeneron Pharmaceuticals 648.70 5.41 0.84% 2.07%
Sanofi 82.43 -4.16 -4.80% -8.05%
Seattle Genetics 170.52 1.99 1.18% 6.76%
Sangamo BioSciences 6.09 -0.30 -4.69% -37.15%
Sanofi 44.81 0.98 2.24% -14.76%
Sarepta Therapeutics 107.83 -1.21 -1.11% 38.44%
Teva Pharmaceutical Industries Ltd 3,591.00 -35.00 -0.97% 14.04%
United Therapeutics 221.66 3.30 1.51% 8.80%
Vertex Pharmaceuticals 303.00 -2.53 -0.83% 55.57%

Indexes Price Day Year
US500 4291 8.06 0.19% -2.49%
USND 13103 -25.50 -0.19% -10.60%
USNDX 13571 -31.97 -0.23% -8.66%

Biogen
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company's marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; GAZYVA indicated for the treatment of CLL and follicular lymphoma; OCREVUS for the treatment of primary progressive MS (PPMS) and relapsing MS (RMS), and other anti-CD20 therapies. The Company's pipeline includes BIIB074; BAN2401; BIIB061; BIIB067, BIIB124, BIIB074, BIIB118 and TMS-007.